Ori Biotech’s Post

View organization page for Ori Biotech, graphic

15,685 followers

⌛ “It’s time to elevate the third pillar of CGT: viability” - Carl Schoellhammer In our newest Ori Spotlight podcast episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs). Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles. 🎧 Listen on Spotify: https://lnkd.in/gmWCkpgG #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

  • No alternative text description for this image
Jason C. Foster

Not afraid of doing hard things

4mo

Great having you on Carl! Thanks for sharing you insights with us

To view or add a comment, sign in

Explore topics